- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06367985
CAPA-IVM Culture With Low Oxygen Tension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Capacitation in-vitro maturation (CAPA-IVM) has recently been advanced in culturing oocytes from the germinal vesicle (GV) stage. This approach is a modified version of conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), following mild stimulation or no controlled ovarian stimulation occurred. Specifically, IVM can be indicated for patients diagnosed with polycystic ovary syndrome (PCOS), a higher number of secondary follicles (constituting nearly 15% of total patients), and treat a range of patients with the risks of ovarian hyperstimulation, venous thromboembolism or ovarian torsion. Additionally, CAPA-IVM helps shorten treatment time, is less expensive, and upgrades patient convenience without multiple follow-up examinations. The live birth rate after the first embryo transfer in the CAPA-IVM group was 35.2%, which was not statistically significantly different from the IVF group at 43.2% (risk difference -8.1%; 95% confidence interval from -16.6% to 0.5%). However, the number of high-quality embryos in each cycle and the cumulative clinical pregnancy rate in CAPA-IVM were still lower than in cIVF.
Moreover, further investigation should be considered due to the lack of high-quality evidence of concurrent reports. Therefore, improving the oocyte maturation conditions in CAPA-IVM to harvest the optimal number of oocytes and the highest possibility of embryo development is essential. Many studies conducted on both animal and human models have demonstrated that the effectiveness of CAPA-IVM depends on various factors. Among these, the environmental culture conditions such as oxygen (O2) concentration play a crucial role in producing healthy mature oocytes. O2 is a vital physical and chemical component of the fallopian tube, uterus and ovarian follicle, it is closely related to metabolic activity, oocyte maturation, and early embryo development. Recent research suggested that O2 concentration may significantly regulate oocyte maturation and early embryo development through hypoxia-inducible factor (HIF). A consensus on the O2 concentration index in the IVM culture environment has not been reached. Oocyte-embedded culture systems have been commonly used in two O2 concentrations, 5% and 20% worldwide. In the human body, cumulus-oocyte complexes (COCs) mature in conditions with low O2 concentrations ranging from 2% to 9%.
Conversely, COCs are exposed to an atmospheric O2 concentration of 20% during IVM manipulation and culture. Although the concentration of 5% mimics the most proper environment in the fallopian tube and uterus, the 20% O2 is widely applied in IVM techniques. The use of high concentrations facilitates a better progression of differentiation processes and increases the maturation rate of oocytes. However, some referential frames indicated that a 20% O2 may pose a risk of reactive oxidative stress (ROS), leading to an imbalance in the ratio of pro-oxidants to antioxidants, resulting in cellular damage. Furthermore, real-time respiration analysis of oocytes cultured at 5% O2 is similar to in vivo-developed oocytes but induced cellular activity and oxygen consumption at 20% O2. The impact of atmospheric O2 concentration (20%) and low O2 concentration (5%) during CAPA-IVM culture in mice shown in the study of Vrije Universiteit Brussel (VUB) - Belgium that the respiratory capability of COCs cultured at 5% O2 was relatively similar to COCs developing and maturing in vivo.
Nonetheless, COCs cultured at 20% O2 increased respiratory activity and oxygen consumption remarkably. The study observed that pre-IVM culture of COCs at 20% O2 caused developmental disruptions. Also, the result was unfavorable if mouse COCs were cultured at the IVM step with 5% O2. Based on these analyses, the researchers hypothesized that a 5% O2 was the optimal culture condition for the pre-IVM step, while a 20% O2 was more relevant to the IVM culture step. Combining these findings with results from VUB and characteristics of the differentiation process in CAPA-IVM oocytes, this study is divided into two main groups, including 5% pre-IVM and 20% IVM versus 20% pre-IVM and IVM) and demonstrates whether this hypothesis should be applied CAPA-IVM in human. The enhancement of the CAPA-IVM culture system leads to improved treatment efficiency of this technique and provides various benefits for patients undergoing assisted reproductive technology.
Study procedure:
Screening for eligibility
- This trial will be conducted at My Duc Hospital, Ho Chi Minh City, Viet Nam.
- Women who are potentially eligible will be provided information about the trial at the time of IVM treatment indication.
- Screening for eligibility will be performed on the day of the first visit when the IVM treatment is indicated.
- Patients will be provided information related to the study together with the informed consent documents. Signed informed consent forms will be obtained by the investigators from all women before the enrolment.
Oocytes will be divided into 2 groups:
Group 1 (includes 2 subgroups: 1A and 1B): Air Oxygen Concentration CAPA-IVM culture T = Total number of oocytes after OR and there are two subgroups.
The number of oocytes is divided below:
If T is an even number:
- Number of oocytes in Group 1A: One oocyte.
- Number of oocytes in Group 1B: T1B = (T-2)/2.
If T is an odd number:
- Number of oocytes in Group 1A: One oocyte.
- Number of oocytes in Group 1B: T1B = ([T-1]-2)/2. One oocyte remainder of the first patient will be assigned to group 1B, and the remainder of the next patient will be assigned to group 2B. Continuing to do so sequentially for the next remainder.
Group 2 (includes 2 subgroups: 2A and 2B): Low Oxygen Concentration CAPA- IVM culture T = Total number of oocytes after OR and there are two subgroups.
The number of oocytes is divided below:
If T is an even number:
- Number of oocytes in Group 2A: One oocyte.
- Number of oocytes in Group 2B: T2B = (T-2)/2.
If T is an odd number:
- Number of oocytes in Group 2A: One oocyte.
- Number of oocytes in Group 2B: T2B = ([T-1]-2)/2. One oocyte remainder of the first patient will be assigned to group 1B, and the remainder of the next patient will be assigned to group 2B. Continuing to do so sequentially for the next remainder.
Group 1A, 2A: Collecting after capacitation: oocyte and cumulus cell.
Group 1B, 2B: Collecting after capacitation: spent media, blank well. Collecting after maturation: spent media, cumulus cell, blank well.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ho Chi Minh City, Vietnam
- My Duc Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-42 years of age
- Diagnosed with polycystic ovary syndrome according to the Rotterdam criteria (2003)
- Indicating CAPA-IVM treatment
- Having at least 40 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication
- Agreeing to have frozen embryo transfer
- Agreeing to participate in the trial
Exclusion Criteria:
- Cycles with oocyte donation, preimplantation Genetic Testing (PGT)
- Couples with severe male factor (sperm concentration <5 million/ml, motility < 10%), surgical sperm retrieval
- Previous history of unexplained immature oocytes after IVF treatment
- Uterine abnormalities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Air Oxygen Concentration CAPA-IVM culture
Half of the COCs will be cultured in the CAPA step and IVM step at 37 degrees Celsius in air oxygen concentration (20%) and 6% carbon dioxide.
|
|
|
Active Comparator: Low Oxygen Concentration CAPA-IVM culture
Half of the COCs will be cultured in the CAPA step at a low oxygen concentration (5%) and IVM step at an air oxygen concentration (20%); all two steps combine 6% carbon dioxide at 37 degrees Celsius.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maturation rate
Time Frame: Two day after oocyte retrieval
|
The oocyte maturation rate was usually defined by MII oocyte number divided by total COCs number
|
Two day after oocyte retrieval
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mode of delivery
Time Frame: At birth
|
Vaginal delivery, C-section (elective, suspected fetal distress, non-progressive labor)
|
At birth
|
|
Total number of oocytes retrieval
Time Frame: On the day of oocyte retrieval
|
Counting the number of oocytes retrieved
|
On the day of oocyte retrieval
|
|
Number of patients with no oocyte retrieved
Time Frame: On the day of oocyte retrieval
|
Counting the number of patients with no oocyte retrieved
|
On the day of oocyte retrieval
|
|
Number of MII oocytes
Time Frame: Two day after oocyte retrieval
|
The oocyte maturation was usually defined by MII oocyte number
|
Two day after oocyte retrieval
|
|
Number of GV oocytes
Time Frame: Two day after oocyte retrieval
|
Counting the number of GV oocytes
|
Two day after oocyte retrieval
|
|
Number of patients with no matured oocyte
Time Frame: Two day after oocyte retrieval
|
Counting the number of patients with no matured oocyte
|
Two day after oocyte retrieval
|
|
Number of 2PN oocytes
Time Frame: 16-18 hours after ICSI
|
Number of zygotes with 2 pronuclei after ICSI
|
16-18 hours after ICSI
|
|
Fertilization rate
Time Frame: 16-18 hours after ICSI
|
Number of fertilized oocytes / number of oocytes inseminated
|
16-18 hours after ICSI
|
|
Abnormal fertilization rate
Time Frame: 16-18 hours after ICSI
|
The percentage of zygotes with 1,3, or 4 pronuclei after ICSI / number of oocytes inseminated
|
16-18 hours after ICSI
|
|
Number of patients with no day-3 embryo
Time Frame: Five day after oocyte retrieval
|
Counting the number of patients with no embryo
|
Five day after oocyte retrieval
|
|
Number of day-3 embryos
Time Frame: Three days after intra-cytoplasmic sperm injection
|
Counting the number of day-3 embryos at 64±2h after ICSI
|
Three days after intra-cytoplasmic sperm injection
|
|
Number of good quality Day-3 embryos
Time Frame: Three days after intra-cytoplasmic sperm injection
|
Number of grade 1 and grade 2 day-3 embryos
|
Three days after intra-cytoplasmic sperm injection
|
|
Number of frozen day-3 embryos
Time Frame: Three days after ICSI
|
Counting the numer of frozen day-3 embryos
|
Three days after ICSI
|
|
Number of blastocyst (day 5 or day 6 embryo)
Time Frame: Five or six days after ICSI
|
Counting the number of blastocyst at 114±2h/140±2h after ICSI
|
Five or six days after ICSI
|
|
Number of patients with no blastocyst
Time Frame: Five or six days after ICSI
|
Counting the number of patients with no blastocyst
|
Five or six days after ICSI
|
|
Number of good quality blastocysts
Time Frame: Five days after intra-cytoplasmic sperm injection
|
Number of grade 1 and grade 2 blastocysts
|
Five days after intra-cytoplasmic sperm injection
|
|
Number of frozen blastocysts
Time Frame: Three days after ICSI
|
Counting the numer of frozen blastocysts
|
Three days after ICSI
|
|
Number of embryos transferred
Time Frame: On the day of embryo transfer
|
Total embryos transferred
|
On the day of embryo transfer
|
|
Quality of embryos transferred (Grade 1, Grade 2, Grade 3)
Time Frame: On the day of embryo transfer
|
The quality of transferred embryo is classified according to Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, 2011; D. Gardner, 1999; D. K. Gardner & Schoolcrati, 1999
|
On the day of embryo transfer
|
|
Positive pregnancy test rate
Time Frame: 11 days after the day of blastocyst transfer and 13 days after the day of day-3 embryo transfer
|
Positive pregnancy test defined as serum human chorionic gonadotropin level greater than 25 mIU/mL
|
11 days after the day of blastocyst transfer and 13 days after the day of day-3 embryo transfer
|
|
Implantation rate
Time Frame: At 3 weeks after embryo transfer after the completion of the embryo transfer
|
Implantation rate is explained as the number of gestational sacs per number of embryos transferred.
|
At 3 weeks after embryo transfer after the completion of the embryo transfer
|
|
Clinical pregnancy rate
Time Frame: 5 weeks after embryo transfer
|
Diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy at 6 weeks or more after the onset of last menstrual period.
In addition to intra-uterine pregnancy, it includes a clinically documented ectopic pregnancy
|
5 weeks after embryo transfer
|
|
Ectopic pregnancy rate
Time Frame: 3 weeks after embryo transfer
|
A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization or histopathology
|
3 weeks after embryo transfer
|
|
Ongoing pregnancy rate
Time Frame: 10 weeks after embryo transfer
|
Ongoing pregnancy is defined as pregnancy with a detectable heart rate at 12 weeks' gestation or beyond.
|
10 weeks after embryo transfer
|
|
Miscarriage <12 weeks rate (Early miscarriage)
Time Frame: 2-10 weeks after embryo transfer
|
Spontaneous loss of pregnancy up to 12 weeks of gestation is referred to as an early
|
2-10 weeks after embryo transfer
|
|
Miscarriage <22 weeks rate (late miscarriage)
Time Frame: At >10 to 20 weeks after the transfer
|
Spontaneous loss of pregnancy between 12 to 22 weeks is termed as late miscarriage
|
At >10 to 20 weeks after the transfer
|
|
Live birth rate
Time Frame: At 22 weeks of gestation
|
Live birth is defined as the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heartbeat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut or the placenta is attached.
A birth weight of 500 grams or more can be used if gestational age is unknown.
Twins counted as one live birth.
|
At 22 weeks of gestation
|
|
Multiple pregnancy rate
Time Frame: 4 weeks after embryo transfer
|
Defined as the presence of more than one gestational sac at early pregnancy ultrasound (6-9 weeks gestation)
|
4 weeks after embryo transfer
|
|
Multiple delivery rate
Time Frame: At 22 weeks' gestation
|
Defined as the complete expulsion or extraction from a woman of more than one fetus, after 22 completed weeks of gestational age, irrespective of whether it is a live birth or stillbirth
|
At 22 weeks' gestation
|
|
Gestational age at birth
Time Frame: At birth
|
Calculated by gestational age of all live births
|
At birth
|
|
Birth weight
Time Frame: At the time of delivery
|
in grams; of singletons and twins
|
At the time of delivery
|
|
Very low birth weight rate
Time Frame: At birth
|
Birth weight less than 1.500 g
|
At birth
|
|
Low birth weight rate
Time Frame: At birth
|
Birth weight less than 2.500 g
|
At birth
|
|
High birth weight rate
Time Frame: At birth
|
Implies growth beyond an absolute birth weight, historically 4.000 g or 4.500 g, regardless of the gestational age
|
At birth
|
|
Very high birth weight rate
Time Frame: At birth
|
Birth weight over than 4.500 g for women with diabetes, and a threshold of 5000 g for women without diabetes
|
At birth
|
|
Small for gestational age rate
Time Frame: At birth
|
Large for gestational age was defined as a birth weight below the 10th percentile
|
At birth
|
|
Large for gestational age rate
Time Frame: At birth
|
Large for gestational age was defined as a birth weight above the 90th percentile
|
At birth
|
|
Hypertension in pregnancy rate
Time Frame: At 20 weeks of gestation or beyond
|
Comprising pregnancy-induced hypertension (PIH), pre-eclampsia (PET), eclampsia, and HELLP syndrome.
|
At 20 weeks of gestation or beyond
|
|
Gestational diabetes mellitus rate
Time Frame: At 24 to 28 weeks of gestation
|
Diagnosed according to the latest version of ADA guidelines. a 75-g OGTT, with plasma glucose measurement when patient is fasting and at 1 and 2 h, at 24-28 weeks of gestation in women not previously diagnosed with diabetes.
|
At 24 to 28 weeks of gestation
|
|
Still birth rate
Time Frame: After 20 completed weeks of gestational age
|
defined as the death of a fetus prior to the complete expulsion or extraction from its mother after 20 completed weeks of gestational age.
The death is determined by the fact that, after such separation, the fetus does not breathe or show any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles.
It includes deaths occurring during labor
|
After 20 completed weeks of gestational age
|
|
Premature birth rate
Time Frame: On the day of delivery
|
Defined as delivery at <24, <28, <32, <37 completed weeks.
A birth that takes place after 22 weeks and before 37 completed weeks of gestational age.
|
On the day of delivery
|
|
Antepartum haemorrhage rate
Time Frame: At birth
|
Defined as bleeding from or into the genital tract, occurring from 24 weeks of pregnancy and prior to the birth of the baby.
|
At birth
|
|
Major congenital abnormalities rate
Time Frame: At birth
|
Structural, functional, and genetic anomalies, that occur during pregnancy, and identified antenatally, at birth, or later in life, and require surgical repair of a defect, or are visually evident, or are life-threatening, or cause death.
Any congenital anomaly will be included as followed definition of congenital abnormalities in Surveillance of Congenital Anomalies by Division of Birth Defects and Developmental Disabilities, NCBDDD, Centers for Disease Control and Prevention (2020).
|
At birth
|
|
Neonatal mortality rate
Time Frame: between eight and 28 days after delivery
|
Neonatal mortality defined as the death of a live-born baby within 28 days of birth.
This can be divided into early neonatal mortality, if death occurs in the first seven days after birth, and late neonatal if death occurs between eight and 28 days after delivery
|
between eight and 28 days after delivery
|
|
NICU admission rate
Time Frame: At birth
|
Counting number of babies admited to neonatal intensive care unit
|
At birth
|
|
Reason for NICU admission
Time Frame: At birth
|
Respiratory distress, Intraventricular Hemorrhage, Necrotizing enterocolitis, Sepsis
|
At birth
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lan N Vuong, MD, PhD, University of Medicine and Pharmacy at Ho Chi Minh City
Publications and helpful links
General Publications
- Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098.
- Fischer B, Bavister BD. Oxygen tension in the oviduct and uterus of rhesus monkeys, hamsters and rabbits. J Reprod Fertil. 1993 Nov;99(2):673-9. doi: 10.1530/jrf.0.0990673.
- Paulson RJ, Fauser BCJM, Vuong LTN, Doody K. Can we modify assisted reproductive technology practice to broaden reproductive care access? Fertil Steril. 2016 May;105(5):1138-1143. doi: 10.1016/j.fertnstert.2016.03.013. Epub 2016 Apr 4.
- Vuong LN, Ho VNA, Ho TM, Dang VQ, Phung TH, Giang NH, Le AH, Pham TD, Wang R, Smitz J, Gilchrist RB, Norman RJ, Mol BW. In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Hum Reprod. 2020 Nov 1;35(11):2537-2547. doi: 10.1093/humrep/deaa240.
- Akin N, Ates G, von Mengden L, Herta AC, Meriggioli C, Billooye K, Stocker WA, Ghesquiere B, Harrison CA, Cools W, Klamt F, Massie A, Smitz J, Anckaert E. Effects of lactate, super-GDF9, and low oxygen tension during bi-phasic in vitro maturation on the bioenergetic profiles of mouse cumulus-oocyte complexdagger. Biol Reprod. 2023 Oct 13;109(4):432-449. doi: 10.1093/biolre/ioad085.
- Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. Electronic address: jgoldstein@asrm.org. In vitro maturation: a committee opinion. Fertil Steril. 2021 Feb;115(2):298-304. doi: 10.1016/j.fertnstert.2020.11.018. Epub 2020 Dec 24.
- Gilchrist RB, Ho TM, De Vos M, Sanchez F, Romero S, Ledger WL, Anckaert E, Vuong LN, Smitz J. A fresh start for IVM: capacitating the oocyte for development using pre-IVM. Hum Reprod Update. 2024 Jan 3;30(1):3-25. doi: 10.1093/humupd/dmad023.
- Zhao X, Liu X, Feng Y, Shi D, Lu F. Regulation of hypoxia-inducible factor 1alpha by optimal oxygen concentration enhances oocyte maturation and early embryonic development in buffalo. Theriogenology. 2023 Aug;206:50-59. doi: 10.1016/j.theriogenology.2023.05.006. Epub 2023 May 8.
- Bahrami M, Cottee PA. Culture conditions for in vitro maturation of oocytes - A review. Reproduction and Breeding. 2022 Jun 1;2(2):31-6
- Increased susceptibility to oxidative stress as a proximate cost of reproduction - Alonso-Alvarez - 2004 - Ecology Letters - Wiley Online Library [Internet]. [cited 2023 Sep 19]. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1461-0248.2004.00594.x
- Herta AC, von Mengden L, Akin N, Billooye K, Coucke W, van Leersum J, Cava-Cami B, Saucedo-Cuevas L, Klamt F, Smitz J, Anckaert E. Characterization of carbohydrate metabolism in in vivo- and in vitro-grown and matured mouse antral folliclesdagger. Biol Reprod. 2022 Oct 11;107(4):998-1013. doi: 10.1093/biolre/ioac124.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 03/24/DD-BVMD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on In Vitro Fertilization
-
Centrum Clinic IVF CenterRecruitingFertilization | Fertilization in VitroTurkey (Türkiye)
-
University of Central FloridaThe IVF Center at Winter ParkRecruitingInVitro Fertilization | In Vitro Fertilisation (IVF) Treatment | Ovarian Aging | In Vitro Fertilization OutcomeUnited States
-
The First Hospital of Jilin UniversityRecruitingFertilization in VitroChina
-
Heilongjiang University of Chinese MedicineNot yet recruitingIn Vitro FertilizationChina
-
Organon and CoCompleted
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
-
Rambam Health Care CampusUnknownFertilization in Vitro
-
IBSA Institut Biochimique SACompletedIn Vitro FertilizationItaly, United Kingdom, Germany, Hungary, Switzerland
Clinical Trials on Air Oxygen Concentration CAPA-IVM culture
-
Mỹ Đức HospitalCompletedIVM | PCOS (Polycystic Ovary Syndrome)Vietnam
-
The First Affiliated Hospital with Nanjing Medical...RecruitingFertility Issues | Embryo Culture | Blastocyst IVFChina
-
Chinese University of Hong KongRecruitingRecurrence | Chronic Subdural Hematoma | OxycephalyHong Kong
-
University Medical Centre MariborSlovenian Research AgencyCompleted
-
Dr. David Yuen Chung CHANRecruitingChronic Subdural HematomaHong Kong